Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
French specialty vaccine company Valneva has announced it is in advanced discussions with European authorities to supply up to 60 million doses of its COVID-19 vaccine, VLA2001. 13 January 2021
Biotechnology
US biotech Checkpoint Therapeutics says it is moving along in its quest to disrupt the ~$25 billion+ immunotherapy market with its anti-PD-L1, cosibelimab, and could be in a position do so as soon as 2022. 13 January 2021
Biotechnology
The US Department of Health and Human Services (HHS) and the Department of Defense (DoD) will purchase additional supply of the casirivimab and imdevimab antibody cocktail for use in non-hospitalized COVID-19 patients to meet the federal government's Operation Warp Speed goals. 13 January 2021
Biotechnology
USA-based microbiome company Vedanta Biosciences today announced that pharma giant Pfizer has made a $25 million investment in the company, as part of the Pfizer Breakthrough Growth Initiative. 12 January 2021
Biotechnology
German family-owned pharma major Boehringer Ingelheim and Enara Bio have entered into a strategic collaboration and licensing agreement to research and develop novel targeted cancer immunotherapies, leveraging Enara Bio’s Dark Antigen discovery platform. 12 January 2021
Biotechnology
USA-based biotech firm bluebird bio has announced a plan to split into two separate companies, with one focusing on severe genetic disease and another on oncology. 12 January 2021
Biotechnology
Switzerland’s Novartis has signed a strategic collaboration agreement to in-license tislelizumab from Sino-American biotech firm BeiGene. 12 January 2021
Biotechnology
US biotech firm BioMarin Pharmaceutical saw its shares close down 9.6% at $81.24 on Monday, after it announced positive top-line results from its ongoing global Phase III GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, which has been issued two brand names – Roctavian and Valrox. 12 January 2021
Biotechnology
The European Medicines Agency today said it has received an application for conditional marketing authorization (CMA) for a COVID-19 vaccine developed by AstraZeneca and Oxford University. 12 January 2021
Biotechnology
Innocoll Holdings, a specialty pharma company wholly-owned by Gurnet Point Capital, a private investment firm focused on health care, has named Louis Pascarella its new chief executive. 11 January 2021
Biotechnology
Norwegian fishing and biotech company Aker BioMarine has entered into an agreement with serial biotech entrepreneur Michael Davidson and his wholly-owned company Medical Food Solutions Research (MFSR). 11 January 2021
Biotechnology
In what has been rare positive news in the search for an effective treatment for Alzheimer’s disease, mid-stage data were released today showing that donanemab, an investigational antibody that targets a modified form of beta amyloid called N3pG, showed significant slowing of decline in a composite measure of cognition and daily function in patients with early symptomatic Alzheimer's disease compared to placebo in the Phase II TRAILBLAZER-ALZ study. 11 January 2021
Biotechnology
Austrian antiviral vaccine and immunodiagnostics specialist Viravaxx has appointed Helmut Brunar, former CEO and chairman at Axentis Pharma, as chief executive officer. 11 January 2021
Biotechnology
US biotech EQRx, which is committed to developing and delivering important new medicines at lower prices, today announced that it has raised $500 million in Series B financing. 11 January 2021
Biotechnology
Hutchison China MediTech, also known as Chi-Med, saw it shares trade down 1.4% to 514.77 pence by mid-morning London trading today, despite revealing a lucrative research collaboration. 11 January 2021
Biotechnology
French pharma major Sanofi today revealed it has entered into an agreement under which it will acquire British privately-held biotech Kymab, which is focused on immune-mediated diseases and immuno-oncology therapeutics. 11 January 2021
Biotechnology
Swiss pharma giant Roche has picked up European approval for Xofluza (baloxavir marboxil), a treatment for flu in people 12 years and over. 11 January 2021
Biotechnology
BioNTech and partner Pfizer on Friday announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB) that shows the antibodies from people who have received the companies’ COVID-19 vaccine, BNT162b2, effectively neutralize SARS-CoV-2 with a key mutation that is also found in two highly transmissible strains. 11 January 2021
Biotechnology
US biotech DiCE Molecules, which is leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology, has announced the completion of an $80 million Series C financing. 11 January 2021
Biotechnology
Shares of UK-based Sareum Holdings closed down more than 30% at 1.75 pence on Friday, after the specialist cancer and autoimmune diseases drug developer reported that the licensing partner for its FLT3+Aurora kinase program has decided not to exercise its option to continue the development of the program. 9 January 2021
All news
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Biotechnology
Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was trading 83% lower at midday on Thursday. 25 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab mafodotin in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for multiple myeloma patients who have received at least one prior line of therapy. 25 November 2024
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $135 million Series B financing round. 25 November 2024
Biotechnology
StemCyte, a subsidiary of StemCyte International, has secured approval from the US Food and Drug Administration for Regenecyte, a cord blood-derived stem cell therapy. 25 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze